Liang Li

发表

A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity

Wenguo Jiang, Xiaofei Wang, Yi Li, 2015, Anti-cancer drugs.

Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma

Y. Zhen, Yi Li, Xiujun Liu, 2017, International journal of nanomedicine.

EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells

R. Shao, Y. Zhen, Yi Li, 2016, Cell Death and Disease.

Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis

Wenguo Jiang, S. Zhang, Y. Zhen, 2013, BMC Cancer.

A novel enediyne‐integrated antibody–drug conjugate shows promising antitumor efficacy against CD30+ lymphomas

Shenghua Zhang, Y. Zhen, Xiaofei Wang, 2018, Molecular oncology.

Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells

Y. Zhen, Xiujun Liu, Liang Li, 2009, Anti-cancer drugs.

Transarterial oily chemoembolization with lidamycin shows potent therapeutic efficacy in VX2 rabbit liver tumor

Liang Li, Genshen Zhong, Zhishan Xu, 2015, OncoTargets and therapy.

An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms

Hebing Chen, R. Shao, Xiaofei Zhou, 2022, Nature Communications.

Hsp90 inhibitor geldanamycin enhances the antitumor efficacy of enediyne lidamycin in association with reduced DNA damage repair.

R. Shao, Y. Zhen, B. Shang, 2014, Asian Pacific journal of cancer prevention : APJCP.

Hsp 90 Inhibitor Geldanamycin Enhances the Antitumor Efficacy of Enediyne Lidamycin in Association with Reduced DNA Damage Repair

R. Shao, Y. Zhen, B. Shang, 2014 .

A novel derivative of geldanamycin and its antitumor activity

Y. Zhen, Liang Li, Hong Liu, 2009 .

An arginine-rich cell penetrating peptide contained anti-gelatinase scFv-LDM fusion protein shows potent antitumor efficacy in pancreatic cancer

Shenghua Zhang, Y. Zhen, Liang Li, 2018, Journal of Cancer.

A Gelatinases‐targeting scFv‐based Fusion Protein Shows Enhanced Antitumour Activity with Endostar against Hepatoma

B. Shang, W. Sheng, Liang Li, 2015, Basic & clinical pharmacology & toxicology.

The Recombinant and Reconstituted Novel Albumin-Lidamycin Conjugate Shows Lasting Tumor Imaging and Intensively Enhanced Therapeutic Efficacy.

R. Shao, S. Zhang, Y. Zhen, 2018, Bioconjugate chemistry.

A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells

Yingge Zhang, R. Shao, Lan Sun, 2020, International journal of nanomedicine.

A tumor-targeting dextran–apoprotein conjugate integrated with enediyne chromophore shows highly potent antitumor efficacy

Shenghua Zhang, Y. Zhen, Yi Li, 2014 .

An albumin-binding domain and targeting peptide-based recombinant protein and its enediyne-integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K-ras mutation

Jing Geng, Y. Zhen, W. Sheng, 2020, Oncology reports.

Construction of a genetically engineered chimeric apoprotein consisting of sequences derived from lidamycin and neocarzinostatin

Wenguo Jiang, Y. Zhen, B. Shang, 2016, Anti-cancer drugs.

Internal enhancement of DNA damage by a novel bispecific antibody‐drug conjugate‐like therapeutics via blockage of mTOR and PD‐L1 signal pathways in pancreatic cancer

R. Shao, Xiujun Liu, Yi Li, 2019, Cancer medicine.

Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma

Liang Li, Hong-juan Yao, Rui Li, 2020, Journal of drug targeting.

A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer

Ping-Tzu Chen, Y. Zhen, Qing-fang Miao, 2017, Oncotarget.

A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.

Shenghua Zhang, Y. Zhen, Xiaofei Wang, 2018, Molecular pharmaceutics.

An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy

Y. Zhen, Jian Xu, Yi Li, 2015, Oncotarget.

MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine.

R. Shao, Y. Zhen, Yi Li, 2014, Oncology reports.

A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis

Y. Zhen, Yue Du, B. Shang, 2017, Oncotarget.

The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation

Wu-li Zhao, R. Shao, G. Jiang, 2015, Oncotarget.

Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.

Y. Zhen, Xiujun Liu, Qing-fang Miao, 2019, Cancer letters.

Different transcriptome profiles between human retinoblastoma Y79 cells and an etoposide-resistant subline reveal a chemoresistance mechanism

R. Shao, Liang Li, Si Zheng, 2018, BMC Ophthalmology.

Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation

Y. Zhen, Yi Li, Wenjun Liu, 2014, Cancer Immunology, Immunotherapy.

EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis

Y. Zhen, Jia‐Lin Wang, Qing-fang Miao, 2018, Acta Pharmacologica Sinica.

Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity

Y. Zhen, Yue Du, Hong-Fei Yi, 2017, Drug delivery.

Recombinant EGFR/MMP‐2 bi‐targeted fusion protein markedly binding to non‐small‐cell lung carcinoma and exerting potent therapeutic efficacy

Y. Zhen, Yue Du, Jian Xu, 2017, Pharmacological research.

Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma.

Y. Zhen, Feng-qiang Wang, B. Shang, 2005, World journal of gastroenterology.

Site-specific PEGylation of lidamycin and its antitumor activity

Y. Zhen, R. Shao, Lei Hu, 2015, Acta pharmaceutica Sinica. B.

Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer

Y. Zhen, Mengkun Zhang, Qing-fang Miao, 2021, Journal of pharmaceutical analysis.